I just checked, and it allowed me to add 467 pieces. So only one tube would have been sold 
E:
Lunette on Times Square:
https://www.facebook.com/Lunettekuukuppi/photos/a.1086824961367772/4631768676873365/
5 Likes
I made some test purchases in the wake of @Torniojaws. A week ago (exactly two weeks after the previous test), only one tube had left the warehouse, so I was able to add 466 pieces to my cart. But what happened then? Sales must have exploded in the last week, because today I could only add 411 tubes to the cart, or is the stock starting to age from the front end?
4 Likes
WED, NOV 03, 2021 16:30 CET
Peptonic Medical (publ) today announced that the company has signed a contract amendment with Orion Corporation in Finland. The amendment concerns Peptonic’s Moisturizing V Cleanser for the Finnish market where the product will be sold under Orion’s own brand Femisan®️.
Orion Corporation has been selling Peptonic’s gel for the treatment of vaginal atrophy under the brand Femisan®️ Vital since spring 2019. Since Orion mainly sell through physical pharmacies, sales have been negatively impacted during the pandemic. However, Orion again sees upward trends in the market and now expands its intimate range with Peptonic’s intimate wash, in Sweden sold under the name VagiVital®️ Moisturizing V Cleanser.
This news caught my eye. How much profit will Peptonic make from this in the short or long term? At least Finland has an aging population, so there might be a market.
3 Likes
I just tried again and it allowed me to add 408 units before giving an error message. So I guess it’s being sold slowly 
So if there were 468 units for sale on September 7th and 408 units left today, then mathematically they are selling (468 - 408) / 58 days = 60 units / 58 days, which is just over 1 unit per day.
Not a frantic pace, but theoretically a new stock order would come in at the end of next year 
4 Likes
Anti-dilution upcoming (TO 1):
PEPTONIC Medical AB
Peptonic Medical intends to carry out a rights issue of approximately SEK 42 million and raises loan financing (Cision)
2021-11-04 17:33
Peptonic Medical AB (publ) (“PMED” or “the Company”) announces today, November 4th, 2021, the intention to carry out a rights issue of units consisting of shares and warrants of series TO1 (“Unit”) with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The proceeds from the Rights Issue and the warrants will mainly be used for the acquisition of Common Sense, for continued commercial launch and international expansion of the VagiVital and Lunettes product series as well as for the development of new products, including clinical studies. The Rights Issue, which is covered to 80 percent by guaranteed commitments from the Company’s largest shareholder Vidarstiftelsen, is expected to provide the Company with a maximum of approximately SEK 42 million and requires a resolution from the Extraordinary General Meeting. The Company’s Board of Directors intends to convene an extraordinary general meeting on December 16, 2021, which is proposed to authorize the Board of Directors to decide on the issue in accordance with the terms below and to determine the date for the implementation of the Rights Issue. The company has, as of today, also entered into an agreement on bridge financing with Vidarstiftelsen, including a loan limit of a total of SEK 25 million, of which SEK 10 million has been utilized. The loan has an annual interest rate of 7% and must be repaid in connection with the termination of the Rights Issue. The Rights Issue will be completed as soon as possible, which is expected to be during the first quarter of 2022.
Proposals for the Extraordinary General Meeting on 16.12.2021:
- Nine (9) shares held entitle the holder to subscribe for one (1) Unit consisting of three (3) shares and two (2) warrants of series TO1.
- Every one (1) share held on the record date determined by the Board, shareholders in PMED receive one (1) unit right. Nine (9) unit rights give the right to subscribe for one (1) Unit.
- The subscription period in the Rights Issue is later determined by the Board.
- The subscription price will be set at SEK 1.98 per Unit, corresponding to SEK 0.66 per share. The warrants are issued free of charge.
- Upon full subscription in the Rights Issue, PMED will receive approximately SEK 42.2 million before issue costs.
- The rights issue is covered to 80 percent by guaranteed commitments from the Vidar Foundation, where compensation is paid at 7% of the guarantee for the commitment excluding own pro rata share of 13.89%.
- If the Rights Issue is oversubscribed, to enable further capital injections and increased ownership diversification, the Board may decide on an over-allotment option (the “Over-allotment Option”) which, when fully subscribed, adds an additional SEK 6 million to the Company. The over-allotment option can also be used as guaranteed compensation to the Vidar Foundation. Upon full exercise of the Over-allotment Option, PMED will receive an additional approximately SEK 5.9 million, corresponding to 14 percent of the Rights Issue.
- Upon full subscription in the Rights Issue, including the over-allotment, the number of shares in the Company will increase from 191,639,642 to 255,519,521, implying an increase in the share capital of SEK 6,387,987.90.
- Upon full exercise of the Over-allotment Option, the number of shares will increase by an additional 9,000,000 shares from 255,519,521 to 264,519,521, implying an increase in the share capital of SEK 900,000.
- The warrant (TO1) has redemption between 14 - 25 November 2022 and can provide an additional SEK 24 - 48 million in the event of full subscription if the over-allotment is also exercised.
- Subscription price: One (1) TO1 gives the right to subscribe for one (1) new share at a price amounting to 70% of the Volume-weighted average price (VWAP) for PMED’s share during the ten (10) trading days which precede 2022-11-11. However, the highest possible subscription price can amount to SEK 1.00 (149% of the subscription price in the rights issue). The minimum exercise price can be SEK 0.50 per share.
- In total, a maximum of 45,586,586 shares will be issued with TO1 as a basis, which can bring in from SEK 24,293,293 to SEK 48,586,587 when used. After the Rights Issue, including over-allotment and after full utilization of TO1, there will be a total of 310,106,107 shares, with a share capital of SEK 30,110,610.70. Compared with today 191,639,642 shares, a total increase of 118,466,465 shares.
- Trading will be admitted for TO1 on Spotlight Stockmarket.
More information behind the link, a fairly long announcement:
1 Like
Well, what’s going to happen to the offering when, with that news, the actual share price is soon below the offering price of 0.66 kr
In 1 week -27.33%
6 Likes
If they decide to lower the price, they’ll also get less money from the offering than they aimed for. I just wonder what else is wrong with Peptonic besides the previously mentioned insider trading suspicion? I haven’t seen any commercials for this company on television at all, in my opinion. At the same time, Procter & Gamble (the company that makes Always pads) is heavily advertising its incontinence products. Peptonic’s ads haven’t been seen in the thread, except for the one described earlier, or have I just missed them?
1 Like
P&G’s market value is over 300 billion euros, and Peptonic’s is about 14 million. I don’t watch TV, but I think it’s very likely that the former’s ads run “a bit” more.
4 Likes
Q3 published:
Group, Lune Group OY incl subsidiary is included from 2020-06-03
2021 THIRD QUARTER (Jul-Sep)
- Net sales of products KSEK 7,234 (9,260)
- Gross profit KSEK 4,493 (6,228), Gross margin 62% (67%)
- Operating loss KSEK -9,853 (-7,264)
- Loss per share SEK -0.05 (-0.04)
2021 FIRST NINE MONTHS (Jan-Sep)
- Net sales of products KSEK 28,949 (13,732)
- Gross profit KSEK 16,060 (9,608), Gross margin 55% (63%)
- Operating loss KSEK – 28,780 (-20,257)
- Loss per share SEK -0.15 (-0.12)
Here’s an excerpt:
The launch of VagiVital in the USA has been postponed until the first quarter of 2022. The reason is that Orion Corporation in Finland currently has problems with the equipment used in the manufacture of VagiVital AktivGel. The equipment will be repaired during the current quarter. The intention is to make an initial launch digitally and use that knowledge as a foundation to sign a partner who can build sales in the USA broadly. The assignment for Peptonic’s US organization has also been expanded with the acquisition of Common Sense with several very important customers.
5 Likes
Is that why Amazon.com UK says: “This product is often out of stock.”?
See: VagiVital Hormone Free Vaginal Gel, 710 g : Amazon.co.uk: Health & Personal Care
Or is it more due to Brexit?
Ugh, I meant to quote Torniojaws’s message, but I messed something up.
1 Like
Peptonic Medical (publ) announced today that LloydsApotek is expanding its distribution with three new products from Peptonic’s range. LloydsApotek already sells VagiVital®️ AktivGel both in its physical stores (pharmacies) and in its own online store. Now, distribution will expand in the same channels with Lunette®️ menstrual cups, Lunette®️ cup wipes, and Lunette®️ intimate wash.
5 Likes
Peptonic Medical AB (publ) has received notice from the Swedish Economic Crime Authority regarding a fine of SEK 0.5 million against the Company
The Company has previously announced that the Swedish Economic Crime Authority initiated an investigation in 2020 regarding a serious insider crime due to measures that the Company had taken within the framework of a financing arrangement between the company and a financial player.
The basis for the claim arises from this case. The company and its representatives intend to continue to cooperate with the authority in the matter.
So, half a million Swedish Kronor, which is about €50,000? Hopefully, it won’t sink the whole company.
It will also be interesting to see what happens next: will Peptonic try to play by the rules from now on, or will there be new controversies?
3 Likes
Launch done:
6 Likes
Cooperation with the UN:
3 Likes
It’s nice that they’re starting a collaboration. I just couldn’t find any mention of how many menstrual cups will be distributed through this cooperation program. Oh well. Hopefully, they can spread the good news about menstrual cups through it.
I’ll continue my monologue. I’ve now seen Lunete’s ad online twice in June. One ad was on LinkedIn. The other was on Facebook, and the latter advertised Lunete’s products on sale. Let’s see how it develops. Will accelerated inflation benefit Lunete or a competitor?
Geeli is now on sale for -50% - original price 3410 yen (€23.9), now 1705 yen (€11.96). But there are only 40 pieces in stock, so it seems to be a clearance sale. We’ll see if they order more. The first batch was confirmed to be at least 468 pieces (most likely 480 or 500 pieces), so that brought in about €10,000 in sales (plus or minus twenty euros) in total.
https://hellofermata.com/en/products/active-moisture-gel-vagivital
2 Likes
2022 second quarter (Apr-Jun)
- Net sales of products KSEK 12 354 (7 356)
- Gross profit KSEK 6 269 (4 863), Gross margin 51% (66%)
- Operating loss KSEK -8 146 (-12 271)
- Loss per share SEK -0.04 (-0.06)
2022 first half year (Jan-Jun)
- Net sales of products KSEK 21 262 (18 747)
- Gross profit KSEK 11 865 (11 439), Gross margin 56% (61%)
- Operating loss KSEK -19 021 (-18 851)
- Loss per share SEK -0.08 (-0.10)
Source: https://www.peptonicmedical.se/half-year-report-january-june-2022-peptonic-medical-ab-publ/
The company seems to be operating at a loss. Will the trend reverse by the end of the year, or will they continue to hit their heads against a wall? Also, has this company had a profitable quarter in a long time? With current results, I certainly won’t be adding to my position in this company; instead, I’ll be looking at other companies to invest my money in.
1 Like
Yeah, I’ve been waiting a bit for the real conquest of the USA to begin, now that the FDA approval is in the bag and sales could start immediately. Something has already been done there, but it’s been pretty low-key or small-scale. But how will they scale it, and when will the marketing drumbeat begin?
THU, SEP 01, 2022
Peptonic Medical (publ) today announced that the company has signed a non-exclusive distribution agreement with German Medical Supplies for the United Arab Emirate market. The agreement concerns Peptonic’s patented self-test to identify amniotic leakage.
Peptonic Medical has during the pandemic observed a growing trend where people want to take greater ownership concerning their own health. This by using self-care solutions contributing to a reduced pressure on health care systems. It is important for users that these self-care solutions are clinically proven.
To meet this trend Peptonic has formed the business unit Medical Consumer. The purpose is to build a unique portfolio that enables women to diagnose, treat and prevent vaginal health issues with clinically proven self-care solutions. The acquisition of Israeli company CommonSense, specialists in vaginal self-tests, at the end of 2021, was an important step
The new business unit is growing rapidly and attracts new partners. Today Peptonic announced it has signed a distribution agreement with German Medical Supplies for distribution and marketing of Peptonic’s patented self-test to identify amniotic leakage during latter parts of pregnancies. The agreement is for the United Arab Emirate and is non-exclusive. German Medical Supplies will sell the product under its own brand name Amnitec Plus™.
German Medical Supplies import and distribute high quality medical devices to UAE. Peptonic’s self-test to identify amniotic leakage is now added to the portfolio. The product has been registered with UAE’s medical device authorities and will be launched during the fall.
What does this mean in practice? An opportunity for this company to get products on sale in new areas, or will it be buried in complete silence at some point? It feels like they are trying hard, but the continuous losses should stop at some point.
6 Likes